Analysts Issue Forecasts for ORIC FY2026 Earnings

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of ORIC Pharmaceuticals in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal expects that the company will post earnings per share of ($2.15) for the year. Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for ORIC Pharmaceuticals' current full-year earnings is ($2.17) per share.

ORIC Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.09.

Several other equities analysts have also recently weighed in on ORIC. Guggenheim reaffirmed a "buy" rating on shares of ORIC Pharmaceuticals in a report on Wednesday, February 26th. Oppenheimer dropped their price target on ORIC Pharmaceuticals from $15.00 to $12.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. HC Wainwright reiterated a "buy" rating and set a $21.00 price objective on shares of ORIC Pharmaceuticals in a research note on Monday, May 5th. JPMorgan Chase & Co. raised their target price on shares of ORIC Pharmaceuticals from $21.00 to $22.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Finally, Wedbush restated an "outperform" rating and issued a $20.00 target price on shares of ORIC Pharmaceuticals in a research report on Thursday, May 29th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $19.17.

ORIC Pharmaceuticals Trading Up 4.8%

Shares of NASDAQ:ORIC traded up $0.45 on Wednesday, reaching $9.84. 359,479 shares of the company's stock were exchanged, compared to its average volume of 770,703. ORIC Pharmaceuticals has a twelve month low of $3.90 and a twelve month high of $14.67. The company has a fifty day moving average of $5.94 and a 200-day moving average of $7.71. The company has a market capitalization of $699.51 million, a price-to-earnings ratio of -5.41 and a beta of 1.49.

Hedge Funds Weigh In On ORIC Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Boxer Capital Management LLC bought a new stake in shares of ORIC Pharmaceuticals during the fourth quarter worth about $13,982,000. MPM Bioimpact LLC acquired a new stake in ORIC Pharmaceuticals during the 1st quarter worth approximately $7,809,000. Vivo Capital LLC grew its holdings in ORIC Pharmaceuticals by 62.8% during the 1st quarter. Vivo Capital LLC now owns 2,080,450 shares of the company's stock worth $11,609,000 after acquiring an additional 802,632 shares during the last quarter. Schonfeld Strategic Advisors LLC acquired a new position in ORIC Pharmaceuticals in the 4th quarter valued at approximately $5,845,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of ORIC Pharmaceuticals by 1,331.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 509,179 shares of the company's stock valued at $2,841,000 after acquiring an additional 473,600 shares during the last quarter. Institutional investors and hedge funds own 95.05% of the company's stock.

Insider Buying and Selling at ORIC Pharmaceuticals

In other news, CFO Dominic Piscitelli sold 2,976 shares of the stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $10.01, for a total value of $29,789.76. Following the completion of the transaction, the chief financial officer now directly owns 102,117 shares in the company, valued at approximately $1,022,191.17. This represents a 2.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 6,200 shares of company stock worth $62,056 over the last 90 days. Insiders own 6.82% of the company's stock.

About ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.